Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SV001 in Healthy Volunteers
NCT06267183Phase 1Recruiting
- Sponsor
- Shanghai Synvida Biotechnology Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing SV001 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 year. Started Jan 2024; status: recruiting.
02
Drugs
SV001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06267183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267183.